NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board
April 10, 2019
Company advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors Appoints Don Nicholson as Board Chairman and Kevin Lee as